Holmusk NeuroBlu behavioral health real-world database surpasses milestone of 4 million patient lives

Holmusk, a company specializing in real-world evidence within the behavioral health sector, has announced that its data analytics platform NeuroBlu has reached the milestone of over 4 million US patient lives. This accomplishment solidifies NeuroBlu as the most extensive real-world database specifically built for behavioral health.

Around 2.5 million new patient lives have been added to NeuroBlu, more than doubling its size. With this augmentation, NeuroBlu’s representation of the US patient population now encompasses individuals from all 50 states, across over 1 million healthcare providers. The newly incorporated dataset includes patients treated in diverse care settings, including inpatient, outpatient, and primary care facilities within some of the nation’s premier behavioral health treatment centers.

“This is a huge leap forward in Holmusk’s mission to transform behavioral health through data-driven evidence,” said Holmusk CEO Nawal Roy. “As we set the new gold standard for real-world evidence in behavioral health, the breadth and depth of structured, longitudinal patient data in NeuroBlu will close the evidence gap and fuel innovation in patient care, care delivery, quality metrics, drug development, and research.”

Holmusk collaborates with its partners to optimize the depth and breadth of the data in Neuroblu by continually integrating new real-world data. The current vast batch of newly added data introduces a substantial amount of structured data for each patient, including rich prescription and treatment histories, along with critical outcome measures across disorders in behavioral health.

Data density is a key principle of the NeuroBlu Database. Holmusk incorporates frequent clinical assessments such as the Patient Health Questionnaire (PHQ-9) and the Mental Status Examination (MSE), as well as outcomes derived through natural language processing of clinical notes. This data density enables protocol design with highly characterized patient cohorts to examine the relationships between behavioral health treatments and outcomes.

NeuroBlu is fundamental to Holmusk mission to transform research and behavioral health care through harnessing real-world data.